Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) EPS (Weighted Average and Diluted) (2023 - 2026)

MBX Biosciences has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.5 for Q1 2026.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.5 for Q1 2026, up 29.58% from a year ago — trailing twelve months through Mar 2026 was -$2.16 (up 66.82% YoY), and the annual figure for FY2025 was -$2.38, up 59.11%.
  • EPS (Weighted Average and Diluted) reached -$0.5 in Q1 2026 per MBX's latest filing, down from -$0.45 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $9.6 in Q4 2024 and bottomed at -$12.62 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.71 (2025), compared with a mean of -$3.27.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 225.0% in 2024 before it crashed 104.69% in 2025.
  • Over 4 years, EPS (Weighted Average and Diluted) stood at -$7.68 in 2023, then soared by 225.0% to $9.6 in 2024, then plummeted by 104.69% to -$0.45 in 2025, then fell by 11.11% to -$0.5 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for MBX at -$0.5 in Q1 2026, -$0.45 in Q4 2025, and -$0.63 in Q3 2025.